ADC Therapeutics (ADCT) Non-Current Debt (2020 - 2026)

ADC Therapeutics (ADCT) has reported Non-Current Debt for 7 consecutive years, with $111.0 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Debt fell 2.44% year-over-year to $111.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $111.0 million (down 2.44% YoY) and the FY2025 annual result came in at $112.5 million, down 1.04% from the prior year.
• Non-Current Debt retreated to $111.0 million in Q1 2026 per ADCT's latest filing, from $112.5 million in the prior quarter.
• Over the last five years, Non-Current Debt for ADCT reached as high as $115.2 million in Q3 2025 and fell as low as $88.4 million in Q1 2022.
• A 5-year average of $106.5 million and a median of $112.5 million in 2025 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt jumped 147.16% — and 2026, when it fell 2.44%.
• Year by year, Non-Current Debt stood at $109.7 million in 2022, then rose by 2.75% to $112.7 million in 2023, then advanced by 0.8% to $113.6 million in 2024, then decreased by 1.04% to $112.5 million in 2025, then retreated by 1.25% to $111.0 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $111.0 million, $112.5 million, and $115.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.